Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn's Disease

SPRING HOUSE, Pa., May 23, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn's disease (CD) and ulcerative colitis (UC),1-4 including data from the SEAVUE study, the first...

from PR Newswire: https://ift.tt/3wuvnGI